DISCLAIMER: This product is strictly for research use only. It is meant solely for laboratory testing and in vitro studies-not for use in or on humans or animals. All details provided on this site are for educational purposes. This item is not intended to be used as a drug, supplement, or cosmetic, and must not be misrepresented as such.
Tesamorelin
Tesamorelin is a synthetic peptide that stimulates the release of growth hormone by mimicking the body's natural Growth Hormone-Releasing Hormone (GHRH). It is FDA-approved for reducing excess abdominal fat in HIV-positive patients with lipodystrophy and is also being studied for its potential effects on body composition, metabolism, and healthy aging.
Variant: 5 mg
Quantity: 1
All peptides arrive in powdered form for stability.
Third-Party Verified Purity
Each batch is tested and certified to meet or exceed 99% purity standards.
Made in the USA
Produced in United States WHO/GMP and ISO 9001:2015 certified facilities.
Rigorous Quality Control
Double-tested to ensure the highest quality for the most effective research.
What is Tesamorelin?
Tesamorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH 1-44) developed to stimulate the pituitary gland's natural production of growth hormone (GH). It is FDA-approved for reducing visceral adipose tissue (VAT) in HIV-positive adults with lipodystrophy and is also being researched for broader applications in fat loss, metabolism, cognitive function, and liver health.
Potential Benefits Shown in Studies
- Increasing natural growth hormone production
- Reducing deep belly fat (visceral adipose tissue)
- Supporting lean muscle growth and recovery
- Improving lipid (cholesterol) profiles
- Enhancing metabolic health and insulin sensitivity
- Supporting cognitive function and memory
- Promoting healthy aging and body composition
Mechanisms of Action
Tesamorelin works by:
- Binding to GHRH receptors in the pituitary gland
- Stimulating pulsatile release of GH, mimicking natural secretion
- Raising circulating IGF-1 levels, supporting tissue growth and metabolism
- Promoting lipolysis (fat breakdown), especially in visceral fat deposits
Unlike exogenous GH, Tesamorelin preserves the body's feedback loops and reduces the risk of GH oversaturation.
Molecular Structure of Tesamorelin
Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-NH₂
Molecular Properties
Tesamorelin Research Highlights
Tesamorelin (Egrifta®) is FDA-approved for reducing visceral adipose tissue (VAT) in patients with HIV-associated lipodystrophy, with clinical trials demonstrating significant VAT loss and improvements in body composition, lipid profile, and insulin sensitivity.
Source: Metical Anti-Aging Evidence
Emerging research is exploring Tesamorelin’s effects beyond HIV lipodystrophy, including reducing hepatic steatosis and liver fibrosis in NAFLD, improving cognitive function, insulin resistance, and other aging-related metabolic markers.
Current Phase II trials are evaluating Tesamorelin’s potential in improving cognitive function in aging HIV populations, and in enhancing motor and sensory recovery after peripheral nerve injuries.
Tesamorelin has been shown to improve lipid metabolism—lowering triglycerides by ~15% and increasing HDL—while maintaining or even enhancing insulin sensitivity, and improving glucose homeostasis.
